IBRX: Company disclosure

Item 7.01 Regulation FD Disclosure. On November 9, 2026, ImmunityBio, Inc. (“ImmunityBio” or the “Company”) issued a press release announcing that ANKTIVA ® plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial . The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information pursuant to Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filings of the Company under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language of such filing, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description of Exhibit 99.1** Press release dated November 9, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). _______________ ** Furnished herewith. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: November 9, 2026 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer